Peru: 6,000 additional volunteers required for trials of Sinopharm's COVID-19 vaccine

09:00 | Lima, Oct. 17.

Researchers from Cayetano Heredia (UPCH) and San Marcos (UNMSM) Universities announced that 6,000 additional volunteers will be required for Phase 3 clinical trials of the inactivated vaccine developed by Chinese laboratory Sinopharm.

This was confirmed by Dr. German Malaga —principal investigator of the vaccine study at Lima-based Cayetano Heredia University— who noted that registration is already open and all potential participants can enroll through the trial website.

As in the past, those entering the site must click on a link saying, "I want to participate," which will allow access to the registration form and be automatically deactivated after all the necessary volunteers have registered.

In statements to Andina news agency, Malaga affirmed that these trials are intended to recruit volunteers from vulnerable populations, that is, those who may be at greater risk of contracting COVID-19.

Thus, the process seeks health workers, members of the National Police and Armed Forces, public transportation drivers and ticket collectors, market vendors, street sweepers, and others whose daily activity involves continuous contact with the public. 

On the other hand, the researchers reiterated that the application of these inactivated vaccines does not mean that inoculated volunteers are protected from COVID-19. Therefore, they stressed the need to keep adhering to the corresponding prevention and social distancing measures.


Published: 10/17/2020
Most read